Setting sail: Atara raises $38.5m for Amgen spin-outs
This article was originally published in Scrip
Executive Summary
Atara Biotherapeutics raised $38.5m in a Series B venture capital round to launch its three drug development ships – the Nina, Pinta and Santa Maria – with drug candidates from Amgen for protein energy wasting associated with end-stage renal disease and ovarian cancer.
You may also be interested in...
Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.
Second Cellectis CAR-T Therapy On Clinical Hold, Dosing Could Be Issue
A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role.
Immunomedics’ ASCENT Confirms Trodelvy’s Efficacy In Triple-Negative Breast Cancer
After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.
Need a specific report? 1000+ reports available
Buy Reports